首页|贝伐珠单抗联合化疗用于高危卵巢癌患者的成本-效果分析

贝伐珠单抗联合化疗用于高危卵巢癌患者的成本-效果分析

Cost-effectiveness of bevacizumab in combination with chemotherapy for high risk ovarian cancer patients

扫码查看
原文链接
  • NETL
  • NSTL
  • 维普
  • 万方数据
目的 从我国医疗卫生角度出发,评价四川地区标准一线化疗加入贝伐珠单抗在高危卵巢癌患者中的成本-效果性.方法 根据International Collaboration on Ovarian Neoplasms 7(ICON-7)临床试验数据,结合我国四川地区的医疗费用水平,进行成本-效果分析,并对结果进行敏感度分析.结果 贝伐珠单抗组与标准化疗组相比,ICER为245 432.92元/年;敏感度分析结果显示,贝伐珠单抗的成本和检查的成本对总成本影响最大,其他参数对其影响较小.结论 从我国医疗卫生角度出发,相对标准化疗,四川地区高危卵巢癌患者一线化疗加入贝伐珠单抗不具有成本效果优势.
Objective To analyze the cost-effectiveness of bevacizumab in combination with chemotherapy for high risk ovarian cancer patients.Methods According to the clinical result of International Collaboration on Ovarian Neoplasms,we analyzed the cost-effectiveness of medical cost in Sichuan province and the sensitivity as well.Results Compared with standard chemotherapy,ICER of the bevacizumab group was RMB 245,432.92 per year.The sensitivity analysis showed that the cost ofbevacizumab and the checking fee had great impact on the total cost among all parameters.Conclusion Bevacizumab in combination with chemotherapy is not cost-effective for high risk ovarian cancer patients.

bevacizumabcost-effectivenessovarian cancersensitivity analysis

干小红、冯维、王颖、李绍芝

展开 >

成都市第五人民医院,成都611130

阆中市人民医院,四川南充637400

中南大学湘雅二医院,长沙410011

新都区妇幼保健院,成都610500

展开 >

贝伐珠单抗 成本效果 卵巢癌 敏感度分析

2013

10.7539/j.issn.1672-2981.2013.09.023

中南药学
湖南省药学会

中南药学

CSTPCD
影响因子：0.736
ISSN：1672-2981
年,卷(期)：2013.11(9)
  • 7
  • 1